Vance G. Fowler, Jr., MD, MHS

Professor of Medicine
Duke University
Durham, North Carolina

Disclosure: Green Cross, Cubist, Cerexa, Durata, Theravance
Debiopharm: Educational fees, Other Financial or Material Support
MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck
Medical Biosurfaces
Locus
Affinergy
Contrafect
Karius
Genentech, Regeneron, Basilea: Research Grant
Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Janssen, xBiotech, Contrafect, Regeneron, Basilea, Destiny.: Consultant
UpToDate: Other Financial or Material Support, Royalties

Presentation(s):

• 21 - We're Part of the Problem: How ID Killed Antibiotic Development

  Thursday, October 3
  10:30 AM – 11:45 AM

• 841 - Implications of C. difficile Treatment on Environmental Contamination: A Randomized Controlled Trial with Microbiologic, Environmental, and Molecular Outcomes

  Thursday, October 3
  2:45 PM – 3:00 PM

• 860 - Oral Therapy For Uncomplicated Staph aureus Bacteremia

  Thursday, October 3
  3:15 PM – 4:30 PM